Levels of cytokine inhibitors: A possible marker of disease activity in childhood dermatomyositis and polymyositis

Clinical and Experimental Rheumatology

Volumn 15, Issue 2, 1997, Pages 211-214

  Prieur, A M ^a,c   Dayer, A ^a,c   Roux Lombard, P ^b,c   Dayer, J M ^b,c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Divisions of Allergy and Immunology   (Canada)

Author keywords

childhood dermatomyositis; cytokine inhibitors; inflammation

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; CASE REPORT; CHILD; DERMATOMYOSITIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; POLYMYOSITIS; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; ANTIGENS, CD; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CYTOKINES; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; POLYMYOSITIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030974506     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. CROWE WE, BOVE KE, LEVINSON JE, et al.: Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982; 25: 126.
2. SILVER RM, MARICQ HR: Childhood dermatomyositis: serial vascular studies. Pediatrics 1989; 83: 278-83.
3. MASTAGLIA FL, WALTON JN: An ultrastructural study of skeletal muscle in polymyositis. J Neur Sci 1971; 12: 473-80.
4. KISSEL JT, MENDELL JR, RAMMOHAN KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314: 329-34.
5. PACHMAN LM, COOKE N: Juvenile dermatomyositis: a clinical and immunologic study. J Pediatr 1980; 96: 226-34.
6. ROUX-LOMBARD P, PUNZI L, HASLER F et al.: Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-9.
7. HAAS RH, DYCK RF, DUBOWITZ V, PEPYS MB: C-reactive protein in childhood dermatomyositis. Ann Rheum Dis 1982; 41: 483-5.
8. HEINRICH PC, CASTELL JV, ANDUS T: Interleukin 6 and the acute phase response. Biochem J 1990; 265: 621-36.
9. BEVAN S, RAYNES JG: IL-1 receptor antagonist regulation of acute phase protein synthesis in human hepatoma cells. J Immunol 1991; 147: 2574-8.
10. DAMTEW B, RZEWNICK D, LOZANSKI G, KUSHNER I: IL-1 receptor antagonist affects the plasma protein response of Hep B3 cells to conditioned medium from lipopolysaccharide-stimulated monocytes. J Immunol 1993; 150: 4001-7.
11. GUERNE P-A, ZURAW BL, VAUGHAN JA, CARSON DA, LOTZ M: Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest 1989; 83; 585-92.
12. GABAY C, GAY-CROSIER F, ROUX-LOMBARD P et al.: Elevated serum levels of interleukin-1 receptor antagonist (IL-1Ra) in polydermatomyositis: a biological marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994; 37: 1744-51.